·糖尿病肾脏疾病·

　　【摘要】 目的 探讨血清中蛋白聚糖-1(syndecan-1)的水平与糖尿病微血管病变的相关性。 方法 选取糖尿病患者53例，其中单纯糖尿病者(DM组)27例，合并糖尿病视网膜病变者(DR组)8例，合并糖尿病慢性肾脏疾病者(CKD组)8例，同时合并DR和CKD者(DR+CKD组)12例。另选取健康对照者(NC)9名。采用酶链免疫吸附试验检测血清中syndecan-1的水平，并分析syndecan-1与DR和CKD的相关性。 结果 DM、DR、CKD、DR+CKD及NC组血清中syndecan-1的浓度分别为(26.79±16.89) ng/ml、(18.83±8.74) ng/ml、(69.44±52.58) ng/ml和(80.33±94.28) ng/ml、(21.59±14.50) ng/ml，各组间比较差异有统计学意义(x2=13.5600，P=0.0088)。CKD、DR+CKD组与NC组比较，差异有统计学意义(x2=4.8000、7.3400，P=0.0284、0.0067)。方差分析结果表明，CKD是决定血清syndecan-1浓度的因素(F=4.9600，P=0.0313)。多重线性回归分析结果表明，血Cr的水平对血清syndecan-1的浓度有极大的决定作用(R2=0.80)。 结论 CKD患者血清syndecan-1水平明显升高;血Cr的水平与糖尿病患者血清syndecan-1的水平明显相关。

　　【关键词】 蛋白聚糖-1(Syndecan-1);血清;糖尿病微血管并发症;糖尿病慢性肾脏疾病;肌酐

A Association of serum syndecan-1 with diabetic microangiopathy WANG Jing-bo, LIU Wei-wei, LYU Gang, et al. Department of Ophthalmology, the 309th Hospital of Chinese People's Liberation Army, Beijing100091，China

Corresponding author: ZHANG Yan-jun, E-mail: zhang2yj@mail.uc.edu

　　【Abstract】 Objective To study the correlation of serum syndecan-1 with diabetic microangiopathy. Methods Serum syndecan-1 was detected by enzyme-linked immunosorbent assay. Association of serum syndecan-1 with diabetic retinopathy and diabetic neuropathy was determined by statistical analysis. Results Fifty-three individuals with diabetes (27 without any diabetic complication, 8 with diabetic retinopathy, 8 with diabetic nephropathy, 12 with diabetic retinopathy plus diabetic neuropathy) and 9 healthy age-matched subjects (control group) were enrolled. Serum syndecan-1 was (21.59±14.50) ng/ml in the group of controls, (26.79±16.89)ng/ml in diabetes without any diabetic complication, (18.83±8.74) ng/ml in diabetic retinopathy,(69.44±52.58) ng/ml in diabetic neuropathy, and (80.33±94.28) ng/ml in diabetic retinopathy plus diabetic neuropathy with differences being significant among 5 groups (x2=13.5600，P=0.0088). The difference in serum syndecan-1 was significant (x2=4.8000，P=0.0284) between diabetic neuropathy group and control group; and significant (x2=7.3400，P=0.0067) between control group and group with diabetic retinopathy and diabetic neuropathy. Diabetic neuropathy was one important determined factor for the levels of serum syndecan-1 (ANOVA, F=4.9600，P=0.0313).We set syndecan-1 as the outcome variable and renal function (urea nitrogen and creatinine) as the independent variables, and multiple linear regression analysis was done. It showed that serum creatinine levels determined greatly on serum syndecan-1 level (R2=0.80). Conclusions In patients with diabetes, serum syndecan-1 is associated with diabetic nephropathy. Serum creatinine level is of a great determined role for the levels of serum syndecan-1 in diabetes.

　　【Key words】 Syndecan-1;Serum;Diabetic microangiopathy;Diabetic kidney disease; Creatinine